A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

A Swiss-led team has developed an AI-driven legged robot that can play badminton against human opponents, demonstrating precise coordination and accuracy. Alice Rizzo reports.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...